Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid



Status:Archived
Conditions:Peripheral Vascular Disease, Renal Impairment / Chronic Kidney Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases, Nephrology / Urology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:July 2010
End Date:February 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular
disease including atherosclerotic cardiovascular disease. This, at least in part, is due to
the chronic inflammatory status usually seen in these patients. Here we try to see if
treatment with extended release nicotinic acid (Niaspan) can reduce their overall
inflammatory burden (in general) and the atherosclerotic plaque inflammation (in
particular).



We found this trial at
2
sites
BWH/FH/DCI Outpatient Dialysis Unit
Boston, Massachusetts 02130
?
mi
from
Boston, MA
Click here to add this to my saved trials
Brigham & Women's Hospital Women's Health Center
850 Boylston Street
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
?
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials